Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

https://doi.org/10.1016/j.bmcl.2006.03.030Get rights and content

Abstract

Small molecule antagonists of the vanilloid receptor TRPV1 (also known as VR1) are disclosed. Pyrrolidinyl ureas such as 8 and 15 (SB-705498) emerged as lead compounds following optimisation of the previously described urea SB-452533. Pharmacological studies using electrophysiological and FLIPR-Ca2+-based assays showed that compounds such as 8 and 15 were potent antagonists versus the multiple chemical and physical modes of TRPV1 activation (namely capsaicin, acid and noxious heat). Furthermore, 15 possessed suitable developability properties to enable progression of this compound into in vivo studies and subsequently clinical development.

Graphical abstract

TRPV1 antagonist activity of SB-705498 (15) and its in vitro and in vivo activity are reported.

  1. Download : Download full-size image

References and notes (10)

  • A. Szallasi et al.

    Pharmacol. Rev.

    (1999)
    M.J. Caterina et al.

    Science

    (2000)
    J.B. Davis et al.

    Nature

    (2000)
  • H.K. Rami et al.

    Drug Discovery Today: Therapeutic Strategies

    (2004)
  • Gunthorpe, M. J.; Hannan, S. L.; Jerman, J. C.; Egerton, J.; Smart, D.; Rami, H. K.; Thompson, M.; Randall, A. D.;...
  • S. Bingham et al.

    J. Pharmacol. Exp. Ther.

    (2005)
  • M.J. Caterina et al.

    Nature

    (1997)
    P. Hayes et al.

    Pain

    (2000)
    M.J. Gunthorpe et al.

    Trends Pharmacol.

    (2002)
There are more references available in the full text version of this article.

Cited by (0)

View full text
Copyright © 2006 Elsevier Ltd. All rights reserved.